UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

European journal of nuclear medicine and molecular imaging, 2018, Vol.45 (1), p.95-101

2018

Volltextzugriff (PDF)

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

European journal of nuclear medicine and molecular imaging, 2018-01, Vol.45 (1), p.95-101

2018

Volltextzugriff (PDF)

30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

Journal der Deutschen Dermatologischen Gesellschaft, 2021-11, Vol.19 (11), p.1682-1697

2021

Volltextzugriff (PDF)

30 years German Dermatologic Cooperative Oncology Group (DeCOG)

Journal der Deutschen Dermatologischen Gesellschaft, 2021-11, Vol.19 (11), p.1682-1697

2021

Volltextzugriff (PDF)

443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011

European journal of cancer (1990), 2015-05, Vol.51 (7), p.861-868

2015

Volltextzugriff (PDF)

4th ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR PIGMENT CELL RESEARCH Berlin, Germany, September 17-19, 1992

Pigment cell research, 1992-10, Vol.5 (4), p.168-168

Garbe, Claus

1992

Volltextzugriff (PDF)

6 Pitfalls in retrospective analysis of data from adjuvant trials

Melanoma research, 1997-04, Vol.7 (2), p.157

Garbe, Claus

1997

Volltextzugriff (PDF)

Absence of merkel cell polyoma virus in cutaneous melanoma

Experimental dermatology, 2011-01, Vol.20 (1), p.78-79

2011

Volltextzugriff (PDF)

Absence of merkel cell polyoma virus in cutaneous melanoma: Letter to the Editor

Experimental dermatology, 2011-01, Vol.20 (1), p.78-79

2011

Volltextzugriff (PDF)

Absolute and relative differential blood count predicts survival of AJCC stage I‐II melanoma patients scheduled for sentinel lymph node biopsy

Australasian journal of dermatology, 2020-08, Vol.61 (3), p.e310-e318

2020

Volltextzugriff (PDF)

Acceptance and reliability of an electronic psychooncological screening of patients with breast cancer: a randomized controlled study

Psychotherapie, Psychosomatik, medizinische Psychologie, 2013-09, Vol.63 (9-10), p.374

2013

Volltextzugriff (PDF)

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy

Cancer Immunology, Immunotherapy, 2018-12, Vol.67 (12), p.1845-1851

2018

Volltextzugriff (PDF)

Acquired Melanocytic Nevi as Risk Factor for Melanoma Development. A Comprehensive Review of Epidemiological Data

Pigment cell research, 2003-06, Vol.16 (3), p.297-306

2003

Volltextzugriff (PDF)

Actinic keratoses

Journal der Deutschen Dermatologischen Gesellschaft, 2012-12, Vol.10 Suppl 7, p.S1-23

2012

Volltextzugriff (PDF)

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

The Lancet (British edition), 2023-09, Vol.402 (10404), p.798-808

2023

Volltextzugriff (PDF)

Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis

European journal of cancer (1990), 2017-09, Vol.82, p.171

2017

Volltextzugriff (PDF)

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

European journal of cancer (1990), 2017-09, Vol.82, p.171-183

2017

Volltextzugriff (PDF)

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

The lancet oncology, 2018-12, Vol.19 (12), p.e720-e725

2018

Volltextzugriff (PDF)

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

The Lancet (British edition), 2022-10, Vol.400 (10358), p.1117-1129

2022

Volltextzugriff (PDF)

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2020-05, Vol.395 (10236), p.1558-1568

2020

Volltextzugriff (PDF)

Adjuvant therapy for stage II melanoma: the need for further studies

European journal of cancer (1990), 2023-08, Vol.189, p.112914-112914, Article 112914

2023

Volltextzugriff (PDF)

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

European journal of cancer (1990), 2013-01, Vol.49 (1), p.166-174

2013

Volltextzugriff (PDF)

Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group

Melanoma research, 2008-10, Vol.18 (5), p.353-358

2008

Volltextzugriff (PDF)

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

European journal of cancer (1990), 2019-09, Vol.119, p.97-106

2019

Volltextzugriff (PDF)

Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry

Journal of the American Academy of Dermatology, 2019-05, Vol.80 (5), p.1299-1307.e7

2019

Volltextzugriff (PDF)

1 – 25 von 506

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

KollektioneBooks on EBSCOhost

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(450)
Mit Volltextzugriff
(380)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

30 years German Dermatologic Cooperative Oncology Group (DeCOG)

443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011

4th ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR PIGMENT CELL RESEARCH Berlin, Germany, September 17-19, 1992

6 Pitfalls in retrospective analysis of data from adjuvant trials

Absence of merkel cell polyoma virus in cutaneous melanoma

Absence of merkel cell polyoma virus in cutaneous melanoma: Letter to the Editor

Absolute and relative differential blood count predicts survival of AJCC stage I‐II melanoma patients scheduled for sentinel lymph node biopsy

Acceptance and reliability of an electronic psychooncological screening of patients with breast cancer: a randomized controlled study

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy

Acquired Melanocytic Nevi as Risk Factor for Melanoma Development. A Comprehensive Review of Epidemiological Data

Actinic keratoses

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Adjuvant therapy for stage II melanoma: the need for further studies

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry

Aktive Filter

Suchergebnisse filtern